EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HBeAg-negative chronic hepatitis B with sequential lamivudine and interferon of 12-month duration and a 6-month overlap Preliminary results



Treatment of HBeAg-negative chronic hepatitis B with sequential lamivudine and interferon of 12-month duration and a 6-month overlap Preliminary results



Hepatology 36(4 Part 2): 641A, October




(PDF 0-2 workdays service: $29.90)

Accession: 035980444

Download citation: RISBibTeXText



Related references

Treatment of HBeAG-negative chronic hepatitis B with sequential lamivudine and interferon-alfa courses of 12-month duration and a 6-month overlap. Journal of Hepatology 38(Supplement 2): 152-153, April, 2003

Efficacy of the treatment of HBeAg-negative chronic hepatitis B patients with lamivudine Results of 12 month therapy. Hepatology 36(4 Part 2): 637A, October, 2002

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. Journal of Gastroenterology and Hepatology 22(10): 1582-1588, 2007

Long-term outcome of patients with HBeAg-negative chronic hepatitis B treated with a 24-month course of interferon alfa. Gastroenterology 120(5 Supplement 1): A 572, April, 2001

Predictive value of ALT and HBV DNA levels in response to sequential combination treatment of lamivudine and interferon in HBeAg-/Anti-Hbe+ chronic hepatitis B. Journal of Hepatology 36(Supplement 1): 104, April, 2002

Higher efficacy of sequential therapy of lamivudine and interferon compared to lamivudine monotherapy in HBeAg positive, chronic hepatitis B patients. Gastroenterology 123(1 Supplement): 69, July, 2002

Retherapy with lamivudine in hbeag-negative chronic hepatitis B patients unresponsive to interferon/peginterferon treatment. Voprosy Virusologii 56(3): 37-40, 2011

Lamivudine treatment in Chinese patients with HBeAg negative chronic hepatitis B Indefinite vs finite duration of therapy. Hepatology 34(4 Pt 2): 325A, October, 2001

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. American Journal of Gastroenterology 100(11): 2463-2471, 2005

Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World Journal of Gastroenterology 11(37): 5882-5887, 2005

Higher efficacy of sequential therapy of lamivudine and interferon-A vs lamivudine monotherapy in patients with HBeAg positive chronic hepatitis B A prospective randomized controlled trial. Journal of Hepatology 40(Suppl 1): 131, April, 2004

Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World Journal of Gastroenterology 7(3): 407-410, 2002

A viral kinetic study using pegylated interferon alpha 2b and lamivudine in naive patients with HBeAG /HBV-DNA chronic hepatitis B Preliminary results. Journal of Hepatology 36(Supplement 1): 94, April, 2002

Long term efficacy of interferon and Thymosin combination in comparison to lamivudine+interferon and interferon monotherapy in patients with HBeAg negative chronic hepatitis B. Journal of Hepatology 38(Supplement 2): 169, April, 2003

Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Journal of Microbiology, Immunology, and Infection 38(4): 262-266, 2005